NYSE:BTX Brooklyn ImmunoTherapeutics (BTX) Stock Forecast, Price & News $2.08 +0.02 (+0.97%) (As of 09/21/2023 ET) Add Compare Share Share Today's Range$2.00▼$2.1850-Day Range$2.05▼$2.9652-Week Range$0.17▼$10.10Volume4,443 shsAverage Volume515,543 shsMarket Capitalization$122.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsHeadlinesOptions ChainSocial MediaProfileChartCompetitorsHeadlinesOptions ChainSocial Media About Brooklyn ImmunoTherapeutics (NYSE:BTX) StockEterna Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in creating transformative regenerative medicine treatments for cancer, blood disorders, and monogenic diseases. It offers IRX-2, a human cell-derived cytokine therapy, studying the safety and efficacy of IRX-2 in patients with head and neck cancer in Phase 2B. The company is headquartered in San Diego, CA.Read More BTX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BTX Stock News HeadlinesSeptember 17, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Brooklyn ImmunoTherapeutics (NYSE:BTX)August 29, 2023 | mirror.co.ukBrooklyn Beckham's wife Nicola Peltz 'to be grilled on camera' over bitter wedding spatSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.June 29, 2023 | health.usnews.comBrooklyn Hospital CenterJune 22, 2023 | ft.comPure joy: the best of Brooklyn’s cool natural wine sceneJune 8, 2023 | forbes.comBest Moving Companies In Brooklyn, New York June 2023May 7, 2023 | usnews.comBrooklyn Technical High SchoolMay 6, 2023 | usnews.comBrooklyn Preparatory High SchoolSeptember 22, 2023 | Behind the Markets (Ad)BREAKING: Tiny biotech successfully treats blindnessThere's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.March 31, 2023 | dailymail.co.ukBrooklyn Beckham: Latest news, views, gossip, photos and videoMarch 18, 2023 | mirror.co.ukBillionaire heiress Nicola Peltz and Brooklyn Beckham saving to buy their 'dream house'March 11, 2023 | mirror.co.ukVictoria Beckham 'fears for son Brooklyn and his wife Nicola' amid wedding lawsuitMarch 1, 2023 | nytimes.comIn Brooklyn, a Tiny Apartment and a Neighborhood Filled With FamiliesMarch 1, 2023 | nypost.comBrooklyn’s priciest rental of 2023 has quickly found a tenantFebruary 26, 2023 | cbsnews.comPolice ask for help identifying driver at the scene of shooting, carjacking in Brooklyn ParkFebruary 23, 2023 | foxnews.comBrooklyn Nets sign head coach Jacque Vaughn to multiyear contract extensionFebruary 19, 2023 | nytimes.comFor Strictly Observant Jews in Brooklyn, the Sabbath ExpandsFebruary 5, 2023 | yahoo.com7 Times Brooklyn Beckham Got Roasted for His Questionable Cooking SkillsJanuary 30, 2023 | dailymail.co.ukCruz Beckham teaches brother Brooklyn how to cook as he whips up a pizza on family outing in MiamiJanuary 28, 2023 | nypost.comLike Brooklyn Beckham, I’m a ‘one of the girls’ husband — and I love itNovember 12, 2022 | mirror.co.ukVictoria Beckham ignores Brooklyn and Nicola's anniversary posts as she teases book clubNovember 4, 2022 | finance.yahoo.comBrooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-QNovember 4, 2022 | finance.yahoo.comBrooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual MeetingNovember 4, 2022 | finance.yahoo.comBrooklyn ImmunoTherapeutics Announces Board ChangesNovember 4, 2022 | finance.yahoo.comBrooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price DeficiencyNovember 4, 2022 | finance.yahoo.comBrooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck CancerNovember 4, 2022 | finance.yahoo.comBrooklyn ImmunoTherapeutics Shares Tick lower After Data From Head and Neck Cancer StudySee More Headlines Receive BTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Brooklyn ImmunoTherapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeNYSE Industry Television Broadcasting Sub-IndustryN/A SectorInformation Current SymbolNYSE:BTX CUSIPN/A CIKN/A WebN/A Phone(212) 582-1199FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares58,826,000Free FloatN/AMarket Cap$122.36 million OptionableOptionable Beta4.61 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMatthew AngelPresident, Chief Executive Officer & DirectorAndrew C. JacksonChief Financial OfficerRoger SidhuChief Medical OfficerJay SialChief Administrative OfficerSandra GurrolaPrincipal Accounting Officer & VP-FinanceKey CompetitorsCinedigmNASDAQ:CIDMReliance Global GroupNASDAQ:RELIWAkernaNASDAQ:KERNWAlfiNASDAQ:ALFIWArqit QuantumNASDAQ:ARQQWView All Competitors BTX Stock - Frequently Asked Questions How have BTX shares performed in 2023? Brooklyn ImmunoTherapeutics' stock was trading at $3.22 on January 1st, 2023. Since then, BTX shares have decreased by 35.4% and is now trading at $2.08. View the best growth stocks for 2023 here. What is Brooklyn ImmunoTherapeutics' stock symbol? Brooklyn ImmunoTherapeutics trades on the New York Stock Exchange (NYSE) under the ticker symbol "BTX." How do I buy shares of Brooklyn ImmunoTherapeutics? Shares of BTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Brooklyn ImmunoTherapeutics' stock price today? One share of BTX stock can currently be purchased for approximately $2.08. How much money does Brooklyn ImmunoTherapeutics make? Brooklyn ImmunoTherapeutics (NYSE:BTX) has a market capitalization of $122.36 million. How can I contact Brooklyn ImmunoTherapeutics? The company can be reached via phone at (212) 582-1199. This page (NYSE:BTX) was last updated on 9/22/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Brooklyn ImmunoTherapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.